Pharma Stocks Face Headwinds in June Quarter; Analysts Name Top Picks

The Indian pharmaceutical industry is bracing for a difficult quarter. When companies report their results for the three months ending in June, investors will see the toll of a brutal comparison: a year ago, the sector was riding a wave of covid-driven demand that inflated both volumes and prices. Now that wave has receded, leaving behind a market that contracted 8.7 percent in value during April and May, with unit volumes down nearly 15 percent in the same stretch.

Analysts at ICICI Direct expect this headwind to persist through the June quarter and beyond. The domestic market remains under pressure, but the real damage is showing up in the numbers that matter most to investors: profit margins. The firm projects that earnings before interest, tax, depreciation, and amortization—the EBITDA metric that often signals a company's operational health—will compress by 300 basis points year-over-year, landing at 19.2 percent. For the companies in their coverage universe, this translates to a grim forecast: just 1 percent revenue growth and declines of 13.3 percent in EBITDA and 15.3 percent in net profit.

The squeeze is coming from multiple directions at once. Raw material costs have climbed. Freight charges remain elevated. In the United States, where Indian pharma companies earn a significant portion of their revenue, pricing pressure is mounting as distributors work through bloated inventory. The healthcare segment—hospitals, diagnostics, and medical devices—faces its own headwind: last year's covid-driven surge in elective procedures and testing has normalized, leaving a high bar for year-over-year comparisons.

BNP Paribas, the global brokerage firm, takes a slightly less pessimistic view but still expects weakness. The firm projects 6 percent revenue growth for its Indian pharma and healthcare coverage universe, but warns that growth will be uneven across companies. Domestic formulations are expected to grow just 1 percent, while US sales will improve only modestly—around 2 percent quarter-over-quarter, or 6 percent year-over-year—even as new product launches attempt to offset the erosion from generic price competition.

For investors trying to navigate this terrain, both firms have identified stocks worth watching. ICICI Direct has assigned buy ratings to a broad list that includes Abbott India, Alkem, Apollo Hospital, Aster DM, Aurobindo, Dr Lal Pathlabs, Dr Reddy's, Fortis Healthcare, Glenmark, Healthcare Global, JB Chemicals, Metropolis, and Natco. BNP Paribas has narrowed its focus, favoring Sun Pharma and Aurobindo Pharma in the pure-play pharma space, with Dr Lal Path Labs and Fortis Healthcare as its healthcare picks. The firm maintains buy ratings on Apollo Hospitals, Divi's Laboratories, Metropolis Healthcare, and Torrent Pharma, while holding a neutral stance on Cipla and Zydus Lifesciences.

The key to separating winners from losers in the coming months will be management commentary on several fronts. Investors should listen closely for updates on raw material sourcing and logistics, the outcome of US Food and Drug Administration inspections, the state of inventory in American distribution channels, and traction in complex or specialty products that command higher margins. The growth outlook for India and emerging markets matters too, as does competitive positioning in the faster-growing segments of devices, diagnostics, and hospital services.

Risks loom. An adverse FDA inspection could derail a company's US business. Currency volatility could squeeze margins further. And in India, the government's push to include more drugs under the National List of Essential Medicines could compress prices on high-volume products. For now, the sector is in a holding pattern, waiting to see which companies can navigate the margin squeeze and emerge with momentum intact.